|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Helicobacter pylori : Friend or foe?显示文摘Helicobacter pylori(H. pylori) is a Gram-negative spiral bacterium that is present in nearly half the world's population. It is the major cause of peptic ulcer disease and a recognized cause of gastric carcinoma. In addition, it is linked to non-ulcer dyspepsia, vitamin B12 deficiency, iron-deficient anemia and immune thrombocytopenic purpura. These conditions are indications for testing and treatment according to current guidelines. An additional indication according to the guidelines is 'anyone with a fear of gastric cancer' which results in nearly every infected person being eligible for eradication treatment. There may be beneficial effects of H. pylori in humans, including protection from gastroesophageal reflux disease and esophageal adenocarcinoma. In addition, universal treatment will be extremely expensive(more than $32 billion in the United States), may expose the patients to adverse effects such as anaphylaxis and Clostridium difficile infection, as well as contributing to antibiotic resistance. There may also be an as yet uncertain effect on the fecal microbiome. There is a need for robust clinical data to assist in decision-making regarding treatment of H. pylori infection. | Stephen David Howard Malnick Ehud Melzer Malka Attali Gabriel Duek Jacob Yahav | 2014 | World Journal of Gastroenterology2014，20，27： | 15 |
| 2 | Detection of Pancreatic Carcinoma (Diagnostic Value of K-ras Mutations in Circulating DNA from Serum)显示文摘 | Livia Theodor Ehud Melzer Michael Sologov Gila Idelman Eitan Friedman Simon Bar-Meir | 1999 | Digestive Diseases and Sciences1999，，10： | 1 |
| 3 | Differential localization of LGR5 and Nanog in clusters of colon cancer stem cells显示文摘 | Abraham Amsterdam Calanit Raanan Letizia Schreiber Ora Freyhan Yakov Fabrikant Ehud Melzer David Givol | 2012 | Acta Histochemica2012，，： | 1 |
| 4 | Perforations following endoscopic retrograde cholangiopancreatography: a single institution experience and surgical recommendations显示文摘 | Rafi Miller Andrew Zbar Yoram Klein Victor Buyeviz Ehud Melzer Bruce N. Mosenkis Eli Mavor | 2013 | The American Journal of Surgery2013，，2： | 1 |
| 5 | Detection of Pancreatic Carcinoma (Diagnostic Value of K-ras Mutations in Circulating DNA from Serum)显示文摘 | Livia Theodor Ehud Melzer Michael Sologov Gila Idelman Eitan Friedman Simon Bar-Meir | 1999 | Digestive Diseases and Sciences1999，，10： | 1 |
| 6 | Mesalamine Did Not Prevent Recurrent Diverticulitis in Phase 3 Controlled Trials显示文摘 | Jeffrey B. Raskin Michael A. Kamm M. Mazen Jamal Juan Márquez Ehud Melzer Robert E. Schoen Tibor Szalóki Karen Barrett Paul Streck | 2014 | Gastroenterology2014，，4： | 1 |
| 7 | Helicobacter pylori infection is associated with advanced colorectal neoplasia显示文摘 | Haim Shmuely Ehud Melzer Michal Braverman Noam Domniz Jacob Yahav | 2013 | Scandinavian Journal of Gastroenterology2013，，1： | 1 |
| 8 | An elderly man with excruciating retrosternal pain and dysphagia显示文摘 | Ami Schattner Yuval Binder Ehud Melzer | 2005 | CMAJ2005，172，： | 1 |
| 9 | Autoimmune hepatitis in southern I srael: A 15‐year multicenter study显示文摘 | Jorge‐Shmuel Delgado Alina Vodonos Stephen Malnick Ofra Kriger Renana Wilkof‐Segev Bertha Delgado Victor Novack Alexander Rosenthal Yoram Menachem Ehud Melzer Alexander Fich | 2013 | Journal of Digestive Diseases2013，，11： | 1 |
| 10 | Five years of fecal microbiota transplantation-an update of the Israeli experience显示文摘AIM To evaluate and describe the efficacy of fecal microbiota transplantation(FMT) for Clostridium difficile infection(CDI) in a national Israeli cohort.METHODS All patients who received FMT for recurrent(recurrence within 8 wk of the previous treatment) or refractory CDI from 2013 through 2017 in all the five medical centers in Israel currently performing FMT were included. Stool donors were screened according to the Israeli Ministry of Health guidelines. Clinical and laboratory data of patients were collected from patients' medical files, and they included indications for FMT, risk factors for CDI and disease severity. Primary outcome was FMT success(at least 2 mo free of CDI-related diarrhea post-FMT). Secondary outcomes included initial response to FMT(cessation of diarrhea within 7 d) and recurrence at 6 mo.RESULTS There were 111 FMTs for CDI, with a median age of 70 years [interquartile range(IQR): 53-82], and 42%(47) males. Fifty patients(45%) were treated via the lower gastrointestinal(LGI, represented only by colonoscopy) route, 37(33%) via capsules, and 24(22%) via the upper gastrointestinal(UGI) route. The overall success rate was 87.4%(97 patients), with no significant difference between routes of administration(P = 0.338). In the univariant analysis, FMT success correlated with milder disease(P = 0.01), ambulatory setting(P < 0.05) and lower Charlson comorbidity score(P < 0.05). In the multivariant analysis, only severe CDI [odd ratio(OR) = 0.14, P < 0.05] and inpatient FMT(OR = 0.19, P < 0.05) were each independently inversely related to FMT success. There were 35(32%) patients younger than 60 years of age, and 14(40%) of them had a background of inflammatory bowel disease.CONCLUSION FMT is a safe and effective treatment for CDI, with capsules emerging as a successful and well-tolerated route. Severe CDI is less likely to respond to FMT. | Sharon A Greenberg Ilan Youngster Nathaniel A Cohen Dan M Livovsky Jacob Strahilevitz Eran Israeli Ehud Melzer Kalman Paz Naomi Fliss-Isakov Nitsan Maharshak | 2018 | World Journal of Gastroenterology2018，24，47： | 0 |
| 11 | Human microbiome: From the bathroom to the bedside显示文摘The human gut contains trillions of bacteria, the major phylae of which include Bacteroidetes, Firmicutes, Actinobacteria and Proteobacteria. Fecal microbial transplantation(FMT) has been known of for manyyears but only recently has been subjected to rigorous examination. We review the evidence regarding FMT for recurrent Clostridium difficile infection which has resulted in it being an approved treatment. In addition there is some evidence for its use in both irritable bowel syndrome and inflammatory bowel disease. Further research is needed in order to define the indications for FMT and the most appropriate method of administration. | Stephen Malnick Ehud Melzer | 2015 | World Journal of Gastrointestinal Pathophysiology2015，6，3： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员